EUVIMEDEUVIMED entdecken
Crossref

Post-COVID-19 rhino-orbito-cerebral mucormycosis—A clinico-mycological study from North India

Juhi Taneja iD, Kuhu Chatterjee, Jaseetha Sasidharan, Syed Zafar Abbas, Anil Kumar Rai, Sujata Raychaudhury, Bhabatosh Das, Asim Das

Medical Mycology · 2023

DOI: 10.1093/mmy/myad067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Mycology, 2023. Verfasst von Juhi Taneja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, ESIC Medical College & Hospital, Faridabad, India. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The second wave of coronavirus disease 2019 (COVID-19), during the early 2021, lead to a devastating outbreak of mucormycosis in India. This study aimed to determine the aetiology, clinical features, comorbidities, and risk factors of rhino-orbito-cerebral mucormycosis (ROCM) and antifungal susceptibility pattern for the isolates. The study included all suspected cases of ROCM in post-COVID-19 patients attending the hospital from May to December 2021. A total of 70 patients were diagnosed with mucormycosis during the study period. The commonest presentations were rhino-orbital and rhino-orbito-cerebral in 35.7% of cases each. Diabetes mellitus was the commonest associated risk factor in 95.7% of all patients, while 78.5% of the patients were treated with corticosteroids in the recent past, and 25.7% presented with active COVID-19 pneumonia. The commonest isolate was Rhizopus arrhizus n = 14, followed by Aspergillus flavus n = 16, A. fumigatus n = 4, A. niger n = 3, Fusarium oxysporumn = 1, and Apophysomyces variabilisn = 1. Fungal species identification was done by phenotypic methods for all the isolates and DNA sequence analysis of 18 isolates, and antifungal susceptibility testing of 30 isolates was performed by commercially prepared HiMIC plate (HiMedia, Mumbai, India) using broth microdilution for amphotericin B, isavuconazole, itraconazole, voriconazole, and posaconazole. The MIC50 and MIC90 of amphotericin B for R. arrhizus strains were 0.25 and 4 μg/ml, respectively; and the MIC50 and MIC90 results for itraconazole, posaconazole, and isavuconazole were 8 and 8, 2 and 2, and 2 and 8 μg/ml, respectively. In vitro data showed that amphotericin B was the most effective antifungal against most species. The commercially available ready-to-use minimum inhibitory concentration plates are user-friendly for performing antifungal susceptibility, which may be useful in choosing appropriate regimens and monitoring emerging resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisCOVID-19AnimalsAntifungal AgentsItraconazoleAmphotericin BIndiaNitrilesPyridinesTriazoles

Stichwörter der Autor:innen

COVID-19-associated mucormycosisamphotericin Bmucormycosisrhino-orbito-cerebral mucormycosis, antifungal susceptibility

Substanzen

Antifungal AgentsItraconazoleAmphotericin BisavuconazoleNitrilesPyridinesTriazoles

Autor:innen und Institutionen

  • Department of Microbiology, ESIC Medical College & Hospital, Faridabad, India.
  • Department of ENT, ESIC Medical College & Hospital, Faridabad, India.
  • Department of Radiology, ESIC Medical College & Hospital, Faridabad, India.
  • Department of Pathology, ESIC Medical College & Hospital, Faridabad, India.
  • Translational Health Science and Technology Institute, Faridabad, India.
  • ESIC Medical College & Hospital, Faridabad, India.

ORCID-Profile: Juhi Taneja

Zitieren

APA

Taneja, J., Chatterjee, K., Sasidharan, J., Abbas, S. Z., Rai, A. K., Raychaudhury, S., Das, B., & Das, A. (2023). Post-COVID-19 rhino-orbito-cerebral mucormycosis—A clinico-mycological study from North India. Medical Mycology. https://doi.org/10.1093/mmy/myad067

Vancouver

Taneja J, Chatterjee K, Sasidharan J, Abbas SZ, Rai AK, Raychaudhury S, et al. Post-COVID-19 rhino-orbito-cerebral mucormycosis—A clinico-mycological study from North India. Medical Mycology. 2023. doi:10.1093/mmy/myad067

BibTeX
@article{Taneja2023,
  author = {Taneja, Juhi and Chatterjee, Kuhu and Sasidharan, Jaseetha and Abbas, Syed Zafar and Rai, Anil Kumar and Raychaudhury, Sujata and Das, Bhabatosh and Das, Asim},
  title = {Post-COVID-19 rhino-orbito-cerebral mucormycosis—A clinico-mycological study from North India},
  journal = {Medical Mycology},
  year = {2023},
  doi = {10.1093/mmy/myad067}
}
Kostenlos starten →